Focus: Trevena is a public biotechnology company focused on GPCR-targeted drug discovery with a commercial-stage product (OLINVYK) and a pipeline spanning cardiovascular and neurology indications. The company operates at modest scale from Chesterbrook, PA.
Profile data last refreshed 13h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Trevena to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
FDA-approved (NDA) opioid-like pain therapeutic with patent protection through 2032; core revenue driver and commercial proof-of-concept for GPCR platform.
Help build intelligence for Trevena
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Trevena's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: BATTALION OIL CORP (BATL) (CIK 0001282648) — EX-10.1
EX-10.1
Trevena Inc Stock (US89365K1007): sector backdrop for a biotech in focus - Ad-hoc-news.de
Trevena Inc Stock (US89365K1007): sector backdrop for a biotech in focus Ad-hoc-news.de
Trevena Inc stock (US89365K1007): Biopharma firm focuses on pain and CNS pipeline amid cash burn con - AD HOC NEWS
Trevena Inc stock (US89365K1007): Biopharma firm focuses on pain and CNS pipeline amid cash burn con AD HOC NEWS
Diabetic Neuropathy Pipeline Set for Significant - openPR.com
Diabetic Neuropathy Pipeline Set for Significant openPR.com
8-K Filing: TREVENA INC (CIK 0001429560) — EXHIBIT 10.1
EXHIBIT 10.1
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
Effects of Selective Sphingosine-1-Phosphate Receptor 1 Agonist, TRV045, on Evoked Pain Tests: An Exploratory, Four-Way Cross-Over Study in Healthy Volunteers.
Oliceridine for postoperative pain and opioid-related complications: The intravenous oliceridine and opioid-related complications (VOLITION) prospective cohort study.
Showing 5 of 10 publications